Assoumou is an infectious diseases physician-scientist at Boston Medical Center. Miller is a research data associate within Dr. Assoumou’s I-CARE (Infectious Complications Assessment and Research) lab ...
The Food and Drug Administration has approved a highly effective new HIV-prevention medication, Gilead Sciences reported Wednesday. In clinical trials, the drug nearly eliminated HIV’s spread among ...
Doctors at DAP Health have begun administering a new twice-a-year injectable HIV prevention medication, which was approved by the Food and Drug Administration in June. Gilead's drug lenacapavir ...
The Food and Drug Administration on Wednesday approved Gilead's twice-yearly antiviral injection for preventing HIV — a milestone that the company and some experts say could help bring the world ...
15don MSN
KZN Health MEC warns that HIV prevention drug Lenacapavir is 'not a licence for risky behaviour'
Lenacapavir, a long-acting injectable form of HIV prevention, is set to revolutionise HIV prevention strategies in South ...
The Kenya Times on MSN
Kenya to introduce long-acting HIV prevention drug in landmark move
Kenya has taken a major step towards expanding HIV prevention options after the Ministry of Health formally recommended the ...
Renewing and sustaining syringe exchanges is essential to protecting public health, saving lives and maintaining the progress ...
Kenya is set to roll out Lenacapavir, a long-acting injectable HIV prevention drug, from January 2026 in a major shift expected to boost adherence, reduce stigma and expand protection, especially ...
The New Times on MSN
Six-month HIV prevention injection set for rollout by year-end
The government plans to introduce lenacapavir, a long-acting injectable drug for HIV prevention, in the last quarter of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback